CBD May Not Have Anti-Seizure Properties On Its Own
A rigorous placebo-controlled trial found that CBD at both low and high doses had no significant effect on cortical excitability or sedation in healthy men, suggesting its anti-epileptic benefits may come primarily from drug interactions with clobazam.
Quick Facts
What This Study Found
Single doses of 30 mg and 700 mg CBD had no significant effects on single-pulse or paired-pulse TMS-EMG measures of cortical excitability, nor on validated CNS sedation tests, compared to placebo — suggesting CBD may lack intrinsic anti-epileptic and sedative properties.
Key Numbers
n=25 healthy males; 3-way crossover; 30 mg and 700 mg CBD vs. placebo; no significant effects on TMS-EMG; some TMS-EEG clusters at 3 and 5 hours post-dose for 700 mg; no effects on sedation battery
How They Did This
Randomized, double-blind, placebo-controlled, 3-way crossover trial in 25 healthy males testing single doses of 30 mg CBD, 700 mg CBD, and placebo using transcranial magnetic stimulation with EMG/EEG and a validated CNS test battery.
Why This Research Matters
If CBD's approved anti-seizure effects are primarily driven by drug interactions with clobazam rather than direct anti-epileptic activity, it fundamentally changes how we understand and prescribe CBD for epilepsy.
The Bigger Picture
This challenges the widespread assumption that CBD is inherently anti-epileptic, suggesting its clinical benefits in Dravet and Lennox-Gastaut syndromes may depend on pharmacokinetic boosting of co-administered medications.
What This Study Doesn't Tell Us
Healthy volunteers (not epilepsy patients); single-dose study doesn't capture chronic effects; males only; TMS measures may not fully capture anti-epileptic mechanisms; some TMS-EEG clusters were significant suggesting subtle effects.
Questions This Raises
- ?Would repeated dosing reveal different effects?
- ?Are there other anti-seizure mechanisms not captured by TMS?
- ?Does CBD have direct effects in diseased brain tissue that don't appear in healthy subjects?
Trust & Context
- Key Stat:
- Evidence Grade:
- Gold-standard RCT design (randomized, double-blind, placebo-controlled, crossover) with objective neurophysiological outcomes, though limited to healthy males and single dosing.
- Study Age:
- Published 2026; reflects current mechanistic understanding of CBD pharmacology.
- Original Title:
- Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
- Published In:
- Clinical pharmacology and therapeutics, 119(1), 147-157 (2026)
- Authors:
- Gorbenko, Andriy A(3), de Cuba, Catherine M K E, de Goede, Annika A, Post, Titiaan E, Bohoslavsky, Roman, Strugala, Pamela K, Heuberger, Jules A A C, Groeneveld, Geert Jan
- Database ID:
- RTHC-08288
Evidence Hierarchy
Frequently Asked Questions
Does CBD directly prevent seizures?
This study suggests possibly not — CBD showed no effect on brain excitability measures at any dose in healthy volunteers, raising the possibility that its anti-seizure benefits come primarily from boosting the effects of other medications like clobazam.
How does CBD work for epilepsy if it doesn't directly affect brain excitability?
CBD inhibits the enzyme that breaks down clobazam (a common co-prescribed anti-seizure medication), effectively increasing clobazam levels in the blood — which may be the primary mechanism behind its epilepsy benefits.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- resin-vs-rosin-vs-live-rosin-difference
- what-is-live-rosin-why-expensive
- terpenes-explained-why-weed-smells-different
- entourage-effect-whole-plant-cannabis
- full-spectrum-vs-broad-spectrum-vs-isolate
Cite This Study
https://rethinkthc.com/research/RTHC-08288APA
Gorbenko, Andriy A; de Cuba, Catherine M K E; de Goede, Annika A; Post, Titiaan E; Bohoslavsky, Roman; Strugala, Pamela K; Heuberger, Jules A A C; Groeneveld, Geert Jan. (2026). Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics, 119(1), 147-157. https://doi.org/10.1002/cpt.70038
MLA
Gorbenko, Andriy A, et al. "Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.." Clinical pharmacology and therapeutics, 2026. https://doi.org/10.1002/cpt.70038
RethinkTHC
RethinkTHC Research Database. "Cannabidiol Lacks Direct Effect on Cortical Excitability: A ..." RTHC-08288. Retrieved from https://rethinkthc.com/research/gorbenko-2026-cannabidiol-lacks-direct-effect
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.